PE20040579A1 - Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen - Google Patents

Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen

Info

Publication number
PE20040579A1
PE20040579A1 PE2003000615A PE2003000615A PE20040579A1 PE 20040579 A1 PE20040579 A1 PE 20040579A1 PE 2003000615 A PE2003000615 A PE 2003000615A PE 2003000615 A PE2003000615 A PE 2003000615A PE 20040579 A1 PE20040579 A1 PE 20040579A1
Authority
PE
Peru
Prior art keywords
acid
carbamates
pharmaceutical compositions
compounds
compositions containing
Prior art date
Application number
PE2003000615A
Other languages
English (en)
Inventor
Quinones Maria Prat
Albero Maria Antonia Buil
Forner Maria Dolors Fernandez
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of PE20040579A1 publication Critical patent/PE20040579A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS FARMACEUTICOS DE CARBAMATO DE FORMULA I DONDE R1 ES FENILO, 2-FURILO, 3-FURILO, ENTRE OTROS; R2 ES ALQUILO INFERIOR, ALQUINILO INFERIOR, CICLOALQUILO SATURADO O INSATURADO, ENTRE OTROS; p ES 1-2 Y EL GRUPO CARBAMATO ESTA EN LAS POSICIONES 2, 3 O 4 DEL ANILLO AZABICICLICO. SON COMPUESTOS PREFERIDOS: ESTER (3R)-1-AZABICICLO[2.2.2]OCT-3-ILICO DEL ACIDO[2-(3,4-DIMETOXIFENIL)ETIL]-(5-METILFURAN-2-ILMETIL)CARBAMICO Y ESTER (3R)-1-AZABICICLO[2.2.2]OCT-3-ILICO DEL ACIDO(5-BROMOTIOFEN-2-ILMETIL)-(2,4,5-TRIFLUOROFENIL)CARBAMICO; ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES MUSCARINICOS M3 UTILIZADAS PARA TRATAR ENFERMEDADES RELATIVAS AL AUMENTO DEL TONO PARASIMPATICO, EXCESIVA SECRESION GLANDULAR Y CONTRACCION DEL MUSCULO LISO
PE2003000615A 2002-06-21 2003-06-18 Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen PE20040579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200201439A ES2203327B1 (es) 2002-06-21 2002-06-21 Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.

Publications (1)

Publication Number Publication Date
PE20040579A1 true PE20040579A1 (es) 2004-09-08

Family

ID=29797397

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000615A PE20040579A1 (es) 2002-06-21 2003-06-18 Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen

Country Status (21)

Country Link
US (3) US7435742B2 (es)
EP (1) EP1515968A2 (es)
JP (1) JP2005533799A (es)
CN (1) CN100363363C (es)
AR (1) AR040275A1 (es)
AU (1) AU2003279384A1 (es)
BR (1) BR0312169A (es)
CA (1) CA2490082A1 (es)
EC (1) ECSP045484A (es)
ES (1) ES2203327B1 (es)
IL (1) IL165775A0 (es)
MX (1) MXPA04012272A (es)
NO (1) NO20050217L (es)
NZ (1) NZ537252A (es)
PE (1) PE20040579A1 (es)
RU (1) RU2321588C2 (es)
TW (1) TW200401776A (es)
UA (1) UA85541C2 (es)
UY (1) UY27850A1 (es)
WO (1) WO2004000840A2 (es)
ZA (1) ZA200410211B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
KR101287460B1 (ko) * 2004-04-22 2013-07-23 베링거 인겔하임 인터내셔날 게엠베하 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
JP2008505118A (ja) * 2004-06-30 2008-02-21 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
KR101360803B1 (ko) 2005-08-15 2014-02-11 베링거 인겔하임 인터내셔날 게엠베하 베타모방제의 제조방법
DE102006028286A1 (de) * 2006-06-20 2007-12-27 Wirsich, Konrad, Dipl.-Ing. (FH) Drehmoment- und rutschfest verbundene aus zwei Teilen bestehende Schaltzahnräder
EP1882691A1 (en) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
US8367696B2 (en) 2007-02-09 2013-02-05 Astellas Pharma Inc. Aza-bridged-ring compound
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP2080507A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
CA2788364C (en) * 2010-01-28 2017-10-31 Theron Pharmaceuticals, Inc. 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
EP2631674A1 (de) * 2012-02-23 2013-08-28 ELMOS Semiconductor AG Verfahren und Sensorsystem zur Vermessung der Eigenschaften einer Übertragungsstrecke eines Messsystems zwischen Sender und Empfänger
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
ES2726664T3 (es) * 2013-07-13 2019-10-08 Beijing Shuobai Pharmaceutical Co Ltd Compuestos de quinina e isómeros ópticos, procedimiento de preparación y uso médico de los mismos
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
EP4185267A1 (en) 2020-07-24 2023-05-31 Genzyme Corporation Pharmaceutical compositions comprising venglustat
JPWO2022145408A1 (es) * 2020-12-28 2022-07-07

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) * 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ATE260277T1 (de) * 2000-06-27 2004-03-15 S A L V A T Lab Sa Von arylalkylaminen abgeleitete carbamate
SK8002003A3 (en) * 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
MXPA04006206A (es) 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.

Also Published As

Publication number Publication date
TW200401776A (en) 2004-02-01
CN100363363C (zh) 2008-01-23
UA85541C2 (ru) 2009-02-10
CA2490082A1 (en) 2003-12-31
ES2203327A1 (es) 2004-04-01
NZ537252A (en) 2006-07-28
NO20050217L (no) 2005-03-18
US20090054480A1 (en) 2009-02-26
US7435742B2 (en) 2008-10-14
BR0312169A (pt) 2005-03-29
AU2003279384A1 (en) 2004-01-06
WO2004000840A3 (en) 2004-02-19
CN1675206A (zh) 2005-09-28
RU2005101409A (ru) 2005-11-20
JP2005533799A (ja) 2005-11-10
EP1515968A2 (en) 2005-03-23
ES2203327B1 (es) 2005-06-16
WO2004000840A2 (en) 2003-12-31
ZA200410211B (en) 2005-09-06
RU2321588C2 (ru) 2008-04-10
US20090005412A1 (en) 2009-01-01
IL165775A0 (en) 2006-01-15
US20060094751A1 (en) 2006-05-04
MXPA04012272A (es) 2005-04-08
UY27850A1 (es) 2003-11-28
ECSP045484A (es) 2005-01-28
AR040275A1 (es) 2005-03-23

Similar Documents

Publication Publication Date Title
PE20040579A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
PE20051152A1 (es) Antagonistas del receptor de acetilcolina muscarinico m3
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
PE20020221A1 (es) CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
PE20140411A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
UY26728A1 (es) Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20040598A1 (es) Tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos como moduladores de la actividad de receptores de quimiocina
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
UY28105A1 (es) Derivados de indazol como antagonistas del crf
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20050193A1 (es) Compuestos heterociclicos utiles como activadores de nurr-1
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed